Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm

Oncology Reviews

Giuseppe Luigi Banna¹  Ornella Cantale¹  Alfredo Addeo²  Alex Friedlaender²  Melissa Bersanelli³  Alessio Cortellini⁴  Marzia Del Re⁵ 

[1] Deparment of Medical Oncology, Portsmouth Hospitals NHS Trust;Department, Geneva University Hospital, Geneva;Medical Oncology Unit, Medicine and Surgery Department, University of Parma, Parma;Medical Oncology Unit, St. Salvatore Hospital, University of L’Aquila, Department of Biotechnological and Applied Clinical Sciences, L’Aquila;Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa, Pisa;

关键词: Immune-checkpoint inhibitor;    PD1;    PD-L1;    lung cancer;    immune-related adverse events.;   

DOI  :  10.4081/oncol.2020.490

来源: DOAJ

【 摘 要 】

Anti-PD1 and anti-PD-L1 agents may have intrinsic and clinically relevant differences in the treatment of non-small cell lung cancer (NSCLC) patients. By reviewing currently available indirect evidence on these agents for NSCLC treatment, highlighting possible inter- and intra-class dissimilarities, anti-PD1 agents showed a higher response rate and a better outcome when combined with chemotherapy for the first-line treatment of patients with squamous and PD-L1 low advanced NSCLC, as compared to anti-PD-L1 agents. Conversely, anti-PD-L1 agents were responsible for less severe adverse events (AEs), particularly, immunerelated AEs. These differences could be explained by their different specific properties. Considering possible differences between anti-PD1 and anti-PD-L1 agents could be clinically relevant for treatment tailoring and inspiring new investigational approaches.

【 授权许可】

Unknown